vs
ExlService Holdings, Inc.（EXLS）与MADRIGAL PHARMACEUTICALS, INC.（MDGL）财务数据对比。点击上方公司名可切换其他公司
ExlService Holdings, Inc.的季度营收约是MADRIGAL PHARMACEUTICALS, INC.的1.7倍（$542.6M vs $321.1M），ExlService Holdings, Inc.净利率更高（11.1% vs -18.2%，领先29.3%），MADRIGAL PHARMACEUTICALS, INC.同比增速更快（210.8% vs 12.7%），ExlService Holdings, Inc.自由现金流更多（$106.5M vs $-133.8M）
ExlService Holdings Inc.是全球知名的分析与数字解决方案服务商，服务覆盖保险、医疗健康、银行金融服务、媒体、零售等多个行业，总部位于纽约，在美国、欧洲、亚洲、拉美、澳大利亚、南非等地拥有超过5.4万名专业从业人员。
本公司是一家美国生物制药企业，成立于2002年，专注于研发新型合成胆汁酸类似物，可用于治疗原发性胆汁性胆管炎、非酒精性脂肪肝、肝硬化等慢性肝病，以及胆汁酸性腹泻等肠道疾病。
EXLS vs MDGL — 直观对比
营收规模更大
EXLS
是对方的1.7倍
$321.1M
营收增速更快
MDGL
高出198.1%
12.7%
净利率更高
EXLS
高出29.3%
-18.2%
自由现金流更多
EXLS
多$240.4M
$-133.8M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $542.6M | $321.1M |
| 净利润 | $60.2M | $-58.6M |
| 毛利率 | 38.6% | — |
| 营业利润率 | 14.4% | -18.6% |
| 净利率 | 11.1% | -18.2% |
| 营收同比 | 12.7% | 210.8% |
| 净利润同比 | 18.9% | 1.4% |
| 每股收益（稀释后） | $0.38 | $-2.55 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXLSMDGL
| Q4 25 | $542.6M | $321.1M | ||
| Q3 25 | $529.6M | $287.3M | ||
| Q2 25 | $514.5M | $212.8M | ||
| Q1 25 | $501.0M | $137.3M | ||
| Q4 24 | $481.4M | $103.3M | ||
| Q3 24 | $472.1M | $62.2M | ||
| Q2 24 | $448.4M | — | ||
| Q1 24 | $436.5M | $0 |
净利润EXLSMDGL
| Q4 25 | $60.2M | $-58.6M | ||
| Q3 25 | $58.2M | $-114.2M | ||
| Q2 25 | $66.1M | $-42.3M | ||
| Q1 25 | $66.6M | $-73.2M | ||
| Q4 24 | $50.7M | $-59.4M | ||
| Q3 24 | $53.0M | $-107.0M | ||
| Q2 24 | $45.8M | — | ||
| Q1 24 | $48.8M | $-147.5M |
毛利率EXLSMDGL
| Q4 25 | 38.6% | — | ||
| Q3 25 | 38.5% | — | ||
| Q2 25 | 37.7% | — | ||
| Q1 25 | 38.6% | 96.7% | ||
| Q4 24 | 38.1% | — | ||
| Q3 24 | 37.8% | — | ||
| Q2 24 | 37.1% | — | ||
| Q1 24 | 37.4% | — |
营业利润率EXLSMDGL
| Q4 25 | 14.4% | -18.6% | ||
| Q3 25 | 14.4% | -39.7% | ||
| Q2 25 | 15.8% | -22.2% | ||
| Q1 25 | 15.7% | -57.8% | ||
| Q4 24 | 14.8% | -64.8% | ||
| Q3 24 | 14.7% | -187.1% | ||
| Q2 24 | 13.7% | — | ||
| Q1 24 | 14.1% | — |
净利率EXLSMDGL
| Q4 25 | 11.1% | -18.2% | ||
| Q3 25 | 11.0% | -39.8% | ||
| Q2 25 | 12.8% | -19.9% | ||
| Q1 25 | 13.3% | -53.4% | ||
| Q4 24 | 10.5% | -57.5% | ||
| Q3 24 | 11.2% | -172.0% | ||
| Q2 24 | 10.2% | — | ||
| Q1 24 | 11.2% | — |
每股收益（稀释后）EXLSMDGL
| Q4 25 | $0.38 | $-2.55 | ||
| Q3 25 | $0.36 | $-5.08 | ||
| Q2 25 | $0.40 | $-1.90 | ||
| Q1 25 | $0.40 | $-3.32 | ||
| Q4 24 | $0.31 | $-2.50 | ||
| Q3 24 | $0.33 | $-4.92 | ||
| Q2 24 | $0.28 | — | ||
| Q1 24 | $0.29 | $-7.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $328.4M | $198.7M |
| 总债务越低越好 | $298.6M | $339.9M |
| 股东权益账面价值 | $912.7M | $602.7M |
| 总资产 | $1.7B | $1.3B |
| 负债/权益比越低杠杆越低 | 0.33× | 0.56× |
8季度趋势，按日历期对齐
现金及短期投资EXLSMDGL
| Q4 25 | $328.4M | $198.7M | ||
| Q3 25 | $390.1M | $295.7M | ||
| Q2 25 | $353.3M | $186.2M | ||
| Q1 25 | $331.4M | $183.6M | ||
| Q4 24 | $340.6M | $100.0M | ||
| Q3 24 | $325.8M | $232.7M | ||
| Q2 24 | $276.1M | — | ||
| Q1 24 | $246.2M | $622.5M |
总债务EXLSMDGL
| Q4 25 | $298.6M | $339.9M | ||
| Q3 25 | $354.8M | $339.8M | ||
| Q2 25 | $260.0M | $118.4M | ||
| Q1 25 | $307.3M | $118.0M | ||
| Q4 24 | $288.5M | $117.6M | ||
| Q3 24 | $344.7M | $117.1M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $116.1M |
股东权益EXLSMDGL
| Q4 25 | $912.7M | $602.7M | ||
| Q3 25 | $952.4M | $625.7M | ||
| Q2 25 | $1.1B | $696.0M | ||
| Q1 25 | $1.0B | $710.6M | ||
| Q4 24 | $929.9M | $754.4M | ||
| Q3 24 | $907.6M | $777.2M | ||
| Q2 24 | $852.6M | — | ||
| Q1 24 | $803.3M | $850.8M |
总资产EXLSMDGL
| Q4 25 | $1.7B | $1.3B | ||
| Q3 25 | $1.7B | $1.4B | ||
| Q2 25 | $1.7B | $1.0B | ||
| Q1 25 | $1.7B | $996.6M | ||
| Q4 24 | $1.6B | $1.0B | ||
| Q3 24 | $1.6B | $1.1B | ||
| Q2 24 | $1.5B | — | ||
| Q1 24 | $1.4B | $1.1B |
负债/权益比EXLSMDGL
| Q4 25 | 0.33× | 0.56× | ||
| Q3 25 | 0.37× | 0.54× | ||
| Q2 25 | 0.25× | 0.17× | ||
| Q1 25 | 0.30× | 0.17× | ||
| Q4 24 | 0.31× | 0.16× | ||
| Q3 24 | 0.38× | 0.15× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $117.4M | $-133.5M |
| 自由现金流经营现金流 - 资本支出 | $106.5M | $-133.8M |
| 自由现金流率自由现金流/营收 | 19.6% | -41.7% |
| 资本支出强度资本支出/营收 | 2.0% | 0.1% |
| 现金转化率经营现金流/净利润 | 1.95× | — |
| 过去12个月自由现金流最近4个季度 | $298.1M | — |
8季度趋势，按日历期对齐
经营现金流EXLSMDGL
| Q4 25 | $117.4M | $-133.5M | ||
| Q3 25 | $120.7M | $79.8M | ||
| Q2 25 | $109.4M | $-47.1M | ||
| Q1 25 | $3.2M | $-88.9M | ||
| Q4 24 | $105.3M | $-104.5M | ||
| Q3 24 | $110.1M | $-67.0M | ||
| Q2 24 | $74.9M | — | ||
| Q1 24 | $-21.9M | $-149.2M |
自由现金流EXLSMDGL
| Q4 25 | $106.5M | $-133.8M | ||
| Q3 25 | $106.4M | $79.0M | ||
| Q2 25 | $95.0M | — | ||
| Q1 25 | $-9.7M | — | ||
| Q4 24 | $95.3M | $-104.7M | ||
| Q3 24 | $97.3M | $-67.8M | ||
| Q2 24 | $62.8M | — | ||
| Q1 24 | $-33.1M | $-149.5M |
自由现金流率EXLSMDGL
| Q4 25 | 19.6% | -41.7% | ||
| Q3 25 | 20.1% | 27.5% | ||
| Q2 25 | 18.5% | — | ||
| Q1 25 | -1.9% | — | ||
| Q4 24 | 19.8% | -101.3% | ||
| Q3 24 | 20.6% | -109.0% | ||
| Q2 24 | 14.0% | — | ||
| Q1 24 | -7.6% | — |
资本支出强度EXLSMDGL
| Q4 25 | 2.0% | 0.1% | ||
| Q3 25 | 2.7% | 0.3% | ||
| Q2 25 | 2.8% | 0.0% | ||
| Q1 25 | 2.6% | 0.0% | ||
| Q4 24 | 2.1% | 0.2% | ||
| Q3 24 | 2.7% | 1.3% | ||
| Q2 24 | 2.7% | — | ||
| Q1 24 | 2.6% | — |
现金转化率EXLSMDGL
| Q4 25 | 1.95× | — | ||
| Q3 25 | 2.08× | — | ||
| Q2 25 | 1.66× | — | ||
| Q1 25 | 0.05× | — | ||
| Q4 24 | 2.08× | — | ||
| Q3 24 | 2.08× | — | ||
| Q2 24 | 1.63× | — | ||
| Q1 24 | -0.45× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXLS
| Insurance | $185.8M | 34% |
| Healthcare And Life Sciences | $142.2M | 26% |
| Banking Capital Markets And Diversified Industries | $122.6M | 23% |
| International Growth Markets | $92.0M | 17% |
MDGL
| Rebates Customer Fees Credits Co Pay Assistance And Other | $208.5M | 65% |
| Other | $76.0M | 24% |
| Chargebacks Discounts For Prompt Pay And Other Allowances | $36.6M | 11% |
